Norgine Announces Closing Of Investment From Goldman Sachs Asset Management
12/15/22, 7:07 AM
Location
amsterdamIndustry
health care
pharmaceutical
biotechnology
Investors
Goldman Sachs Asset Management , Goldman Sachs Asset Management
Today, Norgine Europe B.V. ("Norgine", the "Company"), a leading European specialty pharmaceutical company, announced that the Private Equity business within Goldman Sachs Asset Management has completed its acquisition of a majority stake in the Company. The deal closure is a key milestone in Norgine's history, following over 110 years of family ownership by the Stein Family (who will continue to own a significant stake in the Company). With Goldman Sachs Asset Management as its key partner, Norgine is strongly positioned to deliver on its mission of bringing transformative medicines to market while purposefully putting patients at the heart of its strategy
Company Info
Location
amsterdam, north holland, netherlands
Additional Info
Norgine is a European specialty pharmaceutical company that has strived to deliver innovative medicines to patients for over a century. The Company's extensive European experience, fully integrated infrastructure, and exceptional partnership approach allow it to quickly apply creative solutions to bring patients life-changing medicines that they may not otherwise be able to access. Norgine is proud to have helped 24 million patients around the world in 2021 and generated €505 million in net product sales, representing growth of 10% over 2020.
Norgine has a direct presence in 16 European countries, as well as Australia and New Zealand, and employs over 1,500 people.
Norgine and the sail logo are trademarks of the Norgine group of companies.